Chen BA Biography and Net Worth

of Adicet Bio

Chen Schor is President and CEO of Adicet Bio, a leader in the field of gamma-delta CAR T cell therapies for the treatment of cancer. With more than 25 years of global biopharmaceutical leadership experience, he has led several biotech companies across all stages, from formation, to early-stage discovery, to publicly traded multi-product companies with significant industry partnerships.

Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA and equity financing totaling more than $500 million. He led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL), served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and in leadership positions at several emerging private and public companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit.

He is a board member with the Alliance for Cancer Gene Therapy, a non-for-profit organization committed to advancing new cancer cell and gene therapies, Chairman of the Board of Carbon Biosciences, a gene therapy company, and board member with Karyopharm Therapeutics, a commercial stage oncology company.

Mr. Schor holds a MBA, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

How do I contact Chen Schor BA?: The corporate mailing address for Mr. BA and other Adicet Bio executives is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. Adicet Bio can also be reached via phone at (650) 503-9095 and via email at [email protected]. Learn More on Chen Schor BA's contact information.
Has Chen Schor BA been buying or selling shares of Adicet Bio?: Chen Schor BA has not been actively trading shares of Adicet Bio over the course of the past ninety days. Learn More on Chen Schor BA's trading history.
Who are Adicet Bio's active insiders?: Adicet Bio's insider roster includes Chen BA (), Jay Elliott (COO), Aya Jakobovits (Director), Chen Schor (CEO), and Andrew Sinclair (Director). Learn More on Adicet Bio's active insiders.
Are insiders buying or selling shares of Adicet Bio?: In the last twelve months, Adicet Bio insiders bought shares 3 times. They purchased a total of 223,596 shares worth more than $1,603,934.13. The most recent insider tranaction occured on February, 20th when Major Shareholder Ra Capital Management, L.P. bought 74,751 shares worth more than $543,439.77. Insiders at Adicet Bio own 3.4% of the company. Learn More about insider trades at Adicet Bio.
Information on this page was last updated on 2/20/2026.

Chen Schor BA Insider Trading History at Adicet Bio

Chen Schor BA Buying and Selling Activity at Adicet Bio

Adicet Bio Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Today's Range

Now: $7.76

$7.23

$7.91

50 Day Range

MA: $7.42

$6.11

$8.67

2 Week Range

Now: $7.76

$6.01

$17.44

Volume

154,095 shs

Average Volume

150,236 shs

Market Capitalization

$72.54 million

P/E Ratio

N/A

Dividend Yield